...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >LightCycler PCR Assay for Simultaneous Detection of the H63D and S65C Mutations in the HFE Hemochromatosis Gene Based on Opposite Melting Temperature Shifts
【24h】

LightCycler PCR Assay for Simultaneous Detection of the H63D and S65C Mutations in the HFE Hemochromatosis Gene Based on Opposite Melting Temperature Shifts

机译:基于对立温度变化的同时检测HFE血色素沉着病基因中H63D和S65C突变的LightCycler PCR分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Hereditary hemochromatosis is a common autosomal recessive disorder of iron metabolism, which in its homozygous form occurs in Caucasian populations with a prevalence of 0.2–0.5% (1)(2). Characteristic of the disease is the excessive accumulation of dietary iron and a progressive rise in iron stores. This may lead to serious clinical consequences, including cirrhosis, cardiac failure, diabetes, arthritis, and hepatocellular carcinoma. Treatment involves removal of the iron burden by regular venesection and leads to a normal life expectancy if implemented before the development of cirrhosis (3). Thus, early detection and treatment are critically important. The recent identification of a hemochromatosis gene ( HFE , initially termed HLA-H) by Feder et al. (4) allows early genetic diagnosis and greatly simplifies the screening of a family once affected individuals have been identified. The HFE gene protein product is structurally similar to MHC class I-type molecules and interacts with β2-microglobulin and the transferrin receptor to limit iron absorption (5)(6). Three disease-associated mutations have been detected in the HFE gene. Most individuals with hemochromatosis (80–100%, depending on the population studied) are homozygous for the mutation C282Y. In addition, a small number of compound heterozygotes for C282Y and a second mutation, H63D, may develop clinical iron overload (7). Recently, we demonstrated that a third mutation, S65C, is enriched in hereditary hemochromatosis patients who have a mild form of the disease and who have no mutations at C282 or H63 (8). Although mutations in the HFE gene thus account for most cases of hereditary hemochromatosis, it is clinically important that a minority of hereditary iron overload syndromes are not associated with mutations in the HFE gene. Absence of such mutations thus should not be interpreted to mean that the patient in question does not have hereditary iron overload (1)(2). …
机译:遗传性血色素沉着病是一种常见的铁代谢常染色体隐性遗传疾病,以纯合子形式存在于高加索人群中,患病率为0.2-0.5%(1)(2)。该疾病的特征是饮食中铁的过度积累和铁存储量的逐步增加。这可能会导致严重的临床后果,包括肝硬化,心力衰竭,糖尿病,关节炎和肝细胞癌。如果要在肝硬化发展之前进行治疗,则需要定期穿刺来消除铁的负担,并能达到正常的预期寿命(3)。因此,早期发现和治疗至关重要。 Feder等人最近鉴定了血色素沉着病基因(HFE,最初称为HLA-H)。 (4)可以进行早期遗传诊断,并且一旦确定了受影响的个体,就可以大大简化家庭的筛选。 HFE基因蛋白产物在结构上类似于MHC I类分子,并与β2-微球蛋白和转铁蛋白受体相互作用以限制铁的吸收(5)(6)。在HFE基因中已检测到三个与疾病相关的突变。大多数患有血色素沉着病的个体(80-100%,取决于所研究的人群)对于突变C282Y是纯合的。此外,少数C282Y的化合物杂合子和第二个突变H63D可能会导致临床铁超负荷(7)。最近,我们证明了第三种突变S65C在遗传性血色素沉着病患者中富集,这些患者患有轻度疾病且在C282或H63处无突变(8)。尽管HFE基因的突变是遗传性血色素沉着症的大多数病例,但在临床上重要的是少数遗传性铁超负荷综合征与HFE基因的突变无关。因此,此类突变的缺失不应解释为所讨论的患者没有遗传性铁超负荷(1)(2)。 …

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号